HVO: Record orderbook and CRS Berlin acquisition set the stage for strong growth in 2027

Revenue for H1 2026 declined to £16.3 million with an adjusted EBITDA loss of £4.5 million, but a record orderbook and strong proposal volumes position the group for significant growth in 2027. The acquisition of CRS Berlin expands the clinical platform and is expected to be earnings accretive.Orig…